MNPR:NASDAQ, Monopar Therapeutics Inc.

MNPR stock overview

Monopar Therapeutics Inc. (MNPR:NASDAQ) closed at $69.00 on November 20, 2026, down 1.84% on the day. The stock trades 44.7% below its 52-week high of $124.82 and 37.8% above its 52-week low of $50.07. Over the past year, it lost 24.6%. Monopar Therapeutics Inc. is part of the Health Care sector.

Key figures

Price
$69.00
Day change
-1.84%
Volume
132,610
Average volume
152,512
Market cap
467M+
52-week range
$50.07 – $124.82
50-day average
$79.19
200-day average
$77.43

Price action over the past year

In 252 trading sessions since November 20, 2025, MNPR closed higher on 117 days (46%). Its best day was June 23, 2026 (+19.09%) and its worst was February 4, 2026 (-11.15%). The stock moved 10% or more in a single session 7 times.

Recent signals

MNPR news

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc is the United States-based clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve clinical outcomes for cancer patients. Its pipeline products comprise of Validive, Camsirubicin, and MNPR-101.

Similar stocks

Find more stocks like MNPR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.